Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss

Treatment for diabetes and obesity is rapidly evolving, with multi-targeted approaches taking shape. Medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have set high benchmarks for weight loss and blood sugar management. Now, researchers are exploring compounds that work on several biological pathways simultaneously. Researchers have developed a groundbreaking 'five-in-one' experimental compound that has demonstrated potential to outperform existing therapies by integrating five distinct signaling pathways to regulate metabolism.

This represents a shift from simply mimicking a single hormone to a comprehensive metabolic reset. By addressing glucose control, insulin sensitivity, and energy regulation through multiple avenues, this approach helps to tackle the complex, multifaceted nature of obesity and diabetes more effectively than the current treatments. This development was presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting by Daniela Liskiewicz, PhD, Institute for Diabetes and Obesity, Helmholtz Zentrum Munchen, Neuherberg, and the German Center for Diabetes Research.

The Five-in-One Compound

This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor. Lanifibranor is a molecule that activates three different peroxisome proliferator-activated receptors, known as PPAR-alpha, PPAR-delta, and PPAR-gamma, all of which play critical roles in how the body handles fat and energy. When these five actions work together, they create an effect within the brain and adipose tissue, which is far more potent than administering the individual components alone. Early studies in obese, diabetic mice have shown that this multi-target strategy significantly improves high blood sugar levels and reduces body weight more effectively than even the most powerful existing treatments.

Liskiewicz said, "PPARs are master regulators of metabolism expressed in key metabolic tissues."

The Limitations of Current Therapies

Current treatments, such as GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide, have transformed how metabolic diseases are managed. These drugs work primarily by stimulating insulin secretion, slowing gastric emptying, and signaling satiety to the brain. While they're highly successful, they primarily address appetite and insulin regulation. Researchers have realised that because obesity and diabetes involve deep-seated metabolic dysfunction, targeting only one or two pathways might eventually reach a point where it becomes ineffective for many patients.

Why Five Targets Are Better

The best thing about the five-in-one compound is its 'synergistic' nature. Instead of relying on a single hormone, it adjusts several metabolic controls at once. The GLP-1 and GIP components manage appetite and initial insulin response, while the effect of triple-PPAR activation helps the body in better metabolization of fats and improve long-term insulin sensitivity.

This approach addresses the root cause of metabolic failure rather than just masking the symptoms of weight gain and high blood sugar. By improving how the body uses energy at the cellular level, the compound helps maintain better glycemic control while simultaneously driving higher and more sustainable weight loss.

Future Possibilities

It is important to remember that these promising results were observed in mouse models of obesity and insulin resistance. While these findings offer a significant proof-of-concept, they represent only the first step in a long journey toward human clinical trials. Moving a drug from the lab to the pharmacy shelf requires rigorous testing to ensure safety and effectiveness in diverse human populations.

However, the rapid success of this quintuple agonist signals a shift in how scientists approach metabolic health. As researchers continue to refine these complex, multi-target medications, the future of diabetes and weight management looks increasingly personalised and precise.

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.